Gilead Sciences Set to Test Support After NASH Drug Failed

GILD stock could find a floor near the site of its Jan. 3 bull gap

by Karee Venema

Published on Feb 12, 2019 at 9:28 AM

The shares of Gilead Sciences, Inc. (NASDAQ:GILD) are down 3.1% in electronic trading, after the biotech said a late-stage trial for its Non-Alcoholic Steatohepatitis (NASH) drug, selonsertib, failed to its main goal. Specifically, the treatment did not improve liver scarring when compared to a placebo in the nearly 900 patients enrolled in the study.

Analyst reaction has been swift, with Citigroup and Wells Fargo downgrading GILD stock to the equivalent of a "neutral." Both brokerage firms joined at least two others in cutting their price targets on Gilead, with Wells Fargo setting the lowest bar at $68 -- in line with last night's close at $67.62.

This round of bear notes echoes a recent trend, with GILD stock getting hit with several price-target cuts last week following the company's fourth-quarter earnings miss. Nevertheless, the majority of the 19 covering analysts maintained a "strong buy" rating at last night's close, with not a single "sell" on the books. Plus, the average 12-month price target of $81.75 is a nearly 21% premium to the stock's current perch.

Options traders have been bullish toward Gilead Sciences stock, too. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), GILD's 10-day call/put volume ratio of 4.05 ranks in the 77th annual percentile, meaning calls have been bought to open over puts at a quicker-than-usual clip.

After hitting a five-year low of $60.32 on Dec. 26, GILD rallied all the way up to $70.50 by Feb. 1. However, the shares were rejected by their 100-day moving average, though short-term support has emerged near $65.50 -- home to the security's Jan. 3 bull gap levels.

SAGE Therapeutics Stock Hot Ahead of Earnings
The drug name is scheduled to report on Tuesday
Bear Signal Flashing for This Healthcare Stock Before Earnings
At least four analysts have issued price-target cuts on the stock this week
Signal Says This Retail Stock's on Sale
The shares pulled back this week on news of a Levi Strauss IPO
START YOUR DAY SMARTER.

Get Schaeffer's pre-market news bulletin every morning before the bell rings.
It's free to sign up.


Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


IRA/401K Investment Guide: 2019 Stock Market Crash
Use gold to protect any IRA, 401(k), or retirement account from a looming financial crisis.
3 of Today's Worst Nasdaq Stocks
The stocks are sitting out today's rally in the broader equities market
2019 Rally Continues for Stock Market
The Nasdaq is eyeing its longest weekly win streak since 2016
How American Lithium Tech May Be Poised for 614% Growth
A new lithium technology could change the face of lithium production forever.